Medigene AG 0QGJ.L Stock
Medigene AG Price Chart
Medigene AG 0QGJ.L Financial and Trading Overview
| Medigene AG stock price | 2.19 EUR |
| Previous Close | 2.13 EUR |
| Open | 0 EUR |
| Bid | 0 EUR x N/A |
| Ask | 0 EUR x N/A |
| Day's Range | 0 - 0 EUR |
| 52 Week Range | 0 - 2.58 EUR |
| Volume | 3.9K EUR |
| Avg. Volume | 57 EUR |
| Market Cap | 467.81K EUR |
| Beta (5Y Monthly) | 0.903448 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.406 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0QGJ.L Valuation Measures
| Enterprise Value | 22.82M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.014971421 |
| Price/Book (mrq) | 1.2641009 |
| Enterprise Value/Revenue | 0.73 |
| Enterprise Value/EBITDA | 0.696 |
Trading Information
Medigene AG Stock Price History
| Beta (5Y Monthly) | 0.903448 |
| 52-Week Change | -22.88% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.58 EUR |
| 52 Week Low | 0 EUR |
| 50-Day Moving Average | 1.98 EUR |
| 200-Day Moving Average | 2.15 EUR |
0QGJ.L Share Statistics
| Avg. Volume (3 month) | 57 EUR |
| Avg. Daily Volume (10-Days) | 122 EUR |
| Shares Outstanding | 24.56M |
| Float | 22.9M |
| Short Ratio | N/A |
| % Held by Insiders | 6.66% |
| % Held by Institutions | 4.49% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor | 0.25:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -26.65% |
| Operating Margin (ttm) | 37.38% |
| Gross Margin | 93.65% |
| EBITDA Margin | 104.86% |
Management Effectiveness
| Return on Assets (ttm) | 13.13% |
| Return on Equity (ttm) | -20.35% |
Income Statement
| Revenue (ttm) | 31.25M EUR |
| Revenue Per Share (ttm) | 1.27 EUR |
| Quarterly Revenue Growth (yoy) | -3.40% |
| Gross Profit (ttm) | 29.26M EUR |
| EBITDA | 32.77M EUR |
| Net Income Avi to Common (ttm) | -8330000 EUR |
| Diluted EPS (ttm) | -0.406 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 33.22M EUR |
| Total Cash Per Share (mrq) | 1.35 EUR |
| Total Debt (mrq) | 3.73M EUR |
| Total Debt/Equity (mrq) | 10.06 EUR |
| Current Ratio (mrq) | 5.024 |
| Book Value Per Share (mrq) | 1.507 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 11.98M EUR |
| Levered Free Cash Flow (ttm) | 25.11M EUR |
Profile of Medigene AG
| Country | United Kingdom |
| State | N/A |
| City | Munich |
| Address | Lochhamer Strasse 11 |
| ZIP | 82152 |
| Phone | 49 89 2000 330 |
| Website | https://www.medigene.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 66 |
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.
Q&A For Medigene AG Stock
What is a current 0QGJ.L stock price?
Medigene AG 0QGJ.L stock price today per share is 2.19 EUR.
How to purchase Medigene AG stock?
You can buy 0QGJ.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Medigene AG?
The stock symbol or ticker of Medigene AG is 0QGJ.L.
How many shares does Medigene AG have in circulation?
The max supply of Medigene AG shares is 245.57K.
What is Medigene AG Price to Earnings Ratio (PE Ratio)?
Medigene AG PE Ratio is now.
What was Medigene AG earnings per share over the trailing 12 months (TTM)?
Medigene AG EPS is -0.406 EUR over the trailing 12 months.